Matthew Fust

Mr. Matthew K.
Fust is an Independent Director at Electra Therapeutics, Inc., an Independent Director at Neumora Therapeutics, Inc., an Independent Director at Crinetics Pharmaceuticals, Inc., an Independent Director at Atara Biotherapeutics, Inc. and an Independent Director at Ultragenyx Pharmaceutical, Inc. He is on the Board of Directors at Electra Therapeutics, Inc., Arsenal Biosciences, Inc., Neumora Therapeutics, Inc., Crinetics Pharmaceuticals, Inc., Atara Biotherapeutics, Inc. and Ultragenyx Pharmaceutical, Inc. Mr. Fust was previously employed as an Independent Director by Dermira, Inc., an Independent Director by MacroGenics, Inc., an Executive Vice President-Finance by Onyx Pharmaceuticals, Inc., an Independent Director by Sunesis Pharmaceuticals, Inc., a Chief Financial Officer & Executive Vice President by Jazz Pharmaceuticals, Inc., a Chief Financial Officer by Perlegen Sciences, Inc., a Chief Financial Officer & Senior Vice President by ALZA Corp., and a Manager-Healthcare Strategy Practice by Anderson Consulting Team.
He also served on the board at BlackThorn Therapeutics, Inc. He received his undergraduate degree from the University of Minnesota and an MBA from Stanford Graduate School of Business.